Yazar "Aksoy, S." seçeneğine göre listele

Listeleniyor 1 - 5 / 5
  • [ X ]
    Öğe
    EFFICACY OF ADJUVANT 9-WEEKS TRASTUZUMAB IN NODE-NEGATIVE T1A/B HER2-POSITIVE BREAST CANCER
    (Oxford Univ Press, 2014) Sendur, M. A.; Aksoy, S.; Uncu, D.; Demir, H.; Yuksel, S.; Ekinci, A. S.; Kaplan, A.
    [Abstract Not Available]
  • [ X ]
    Öğe
    Multiple primary malignant neoplasms: Multi-center results from Turkey
    (Imprimatur Publications, 2012) Babacan, N. A.; Aksoy, S.; Cetin, B.; Ozdemir, N. Y.; Benekli, M.; Uyeturk, U.; Kaplan, M. Ali
    Purpose: Multiple primary malignant neoplasms (MPMNs) are defined as a diagnosis of two or more independent primary malignancies of different histologies/origins in an individual. The frequency of MPMN is being increasing. In this study we aimed to determine the frequency and clinical features of second primary cancers (SPCs). Methods: From January 1990 to December 2010, patients with MPMNs were screened in 5 centers. Data were obtained retrospectively from hospital charts. Results: Three hundred seventy-seven patients with MPMNs were evaluated. The median age at initial cancer diagnosis was 61 years (range 18-88). The median age at second cancer was 64 years (range 20-89). The median time between two cancer diagnoses was 15 months (range 0-504). Male to female ratio was 1.44 (M/F 223/154). The most frequent initial cancer types were head and neck (54 patients, 14.3%), breast (54 patients, 14.3%), and colorectal (43 patients, 11.4%). The most frequent second cancer types were lung (76 patients, 20.2%), colorectal (39 patients, 10.3%) and breast (33 patients, 8.8%). The most common cancer pairs in females were breast-gynecologic cancers (15 patients, 9.7%), colorectal-breast cancers (9 patients, 5.8%) and breast-colorectal cancers (7 patients, 4.5%). The most common cancer pairs in males were head and neck-lung cancers (29 patients, 13%), bladder-lung cancers (9 patients, 4%), and bladder-prostate cancers (7 patients, 3%). The median follow up was 36 months (range 1-595). Conclusion: Physicians should be aware of SPCs probabilities. Newly developed suspicious lesions should be evaluated rigorously. Histopathologic evaluations of suspicious lesions for second tumors should be used extensively if needed. In our series, the most common pairs were breast-gynecologic cancers in females and head and neck-lung cancers in males.
  • [ X ]
    Öğe
    Outcome of operable male breast carcinoma: One hundred eighteen patients
    (Amer Soc Clinical Oncology, 2011) Arslan, U. Yalcintas; Oksuzoglu, O. B.; Ozdemir, N.; Aksoy, S.; Alkis, N.; Durnali, A. Gok; Kaplan, M. A.
    [Abstract Not Available]
  • [ X ]
    Öğe
    Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results
    (Oxford Univ Press, 2018) Esin, E.; Oksuzoglu, O. B. Cakmak; Bilici, A.; Cicin, I.; Aksoy, S.; Alacacioglu, A.; Kaplan, M. A.
    [Abstract Not Available]
  • [ X ]
    Öğe
    Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes
    (Springer, 2019) Esin, Ece; Oksuzoglu, B.; Bilici, A.; Cicin, I.; Kostek, O.; Kaplan, M. A.; Aksoy, S.
    PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study was conducted by Turkish Oncology Group and included 317 patients' data from 36 centers.ResultsMedian age was 51 (22-82). Median PFS was 28.5months, while median OS was 40.3months. Patients with brain metastases (n: 13, 4.1%) had worse PFS (16.8m vs. 28.5m; p=0.002) and OS (26.7m vs. 40.3m; p=0.009). Patients older than 65years of age (n: 42, 13.2%) had significantly lower OS results (19.8m vs. 40.3m; p=0.01). Two hundred sixty-eight patients (86.7%) received docetaxel while 37 patients (11.7%) received paclitaxel. PFS and OS were similar between taxane groups. In eight patients (2.5%), 5-40% ejection fraction decrement from baseline was detected without any clinical sign of heart failure.ConclusionsOur RLP trial included only visceral metastatic, trastuzumab-naive BC patients including cases with brain involvement who received PTT combination in the first-line treatment. Regardless of negative prognostic characteristics, our results are in parallel with pivotal trial. Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment. Taxane selection can be personalized and endocrine maintenance may further improve outcomes after taxanes were discontinued. To our knowledge, this is the largest scale real-life clinical practice study of pertuzumab-trastuzumab-taxane therapy to date.